Nektaria Papadopoulou, Louise Wainwright, Vicky Lacey, Jane Wrigley, Jamie Wood, Sumanjeet Malhi, Louise Woolley, Jason King, Simon Jiang, and Rajendra Kumari
There are currently limited treatment options for hepatocellular carcinoma (HCC), which is a highly aggressive cancer type. While immunotherapies such as checkpoint inhibitors are being trialled clinically, suitable preclinical models are needed to optimise and speed their development.
Subcutaneous syngeneic models are the common preclinical choice to assess the impact of immunotherapy on tumour growth and tumour invading leucocytes; however, orthotopic models have a more relevant tumour microenvironment and are more closely comparable to patient disease factors.
CrownBio has therefore developed orthotopic, syngeneic HCC models which are also bioluminescent, which allows non-invasive and real time longitudinal monitoring of tumour burden, and assessment of checkpoint inhibitors to treat HCC.